Balsalazide

Balsalazide

Clinical data
Pregnancy category	US: B (No risk in non-human studies)
ATC code	A07EC04 (WHO)
Legal status
Legal status	POM [UK]
Pharmacokinetic data
Bioavailability	<1%
Protein binding	≥99%
Elimination half-life	12hr
Identifiers
IUPAC name 5-[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl-2-hydroxy-benzoic acid
CAS Number	80573-04-2
PubChem CID	5362070
DrugBank	APRD00141
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H15N3O6
Molar mass	357.318 g/mol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.

The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.

Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.

External links

• FDA Colazal Info
• Colazal Label (PDF)